ATRA - Atara Biotherapeutics, Inc.
| Previous Close | 14.99 |
| Open | 14.81 |
| Bid | 0.00 x 1300 |
| Ask | 0.00 x 1300 |
| Day's Range | 14.51 - 15.98 |
| 52 Week Range | 11.89 - 43.95 |
| Volume | 742,020 |
| Avg. Volume | 847,173 |
| Market Cap | 840.775M |
| Beta (3Y Monthly) | 2.94 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.07 |
| Earnings Date | Nov 2, 2017 - Nov 6, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.71 |
- Benzinga
The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 11) Ardelyx Inc (NASDAQ: ARDX ) Avedro Inc (NASDAQ: AVDR ...
- GlobeNewswire
Atara Biotherapeutics Reports Early Findings of Potential Efficacy from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019
Atara Biotherapeutics, Inc. (ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the presentation of initial efficacy data as well as updated safety results from its ongoing Phase 1 study of ATA188 for the treatment of progressive forms of multiple sclerosis (MS). The data are featured in a late-breaking poster presentation at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held in Stockholm, Sweden, September 11-13, 2019.
- GuruFocus.com
3 Small-Cap Stock Picks From Seth Klarman
The guru has high conviction in these stocks Continue reading...
- GuruFocus.com
Baupost's Seth Klarman Dives Further Into Translate Bio
Guru adds to position in biotech company that focuses on genetic diseases Continue reading...
- GlobeNewswire
Atara Biotherapeutics to Present Initial Efficacy and Additional Safety Results from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019
Atara Biotherapeutics, Inc. (ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced it will present for the first time initial efficacy data as well as updated safety results from its ongoing Phase 1 study of ATA188 for the treatment of progressive forms of multiple sclerosis (MS) in a late-breaking poster presentation at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), September 11-13, 2019, in Stockholm, Sweden. ATA188 is an off-the-shelf, allogeneic T-cell immunotherapy that targets Epstein-Barr Virus (EBV)-infected B cells, which we believe play a fundamental role in the pathogenesis of MS.
- GlobeNewswire
Atara Biotherapeutics to Participate in Citi 14th Annual Biotech Conference
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- Zacks
Are Options Traders Betting on a Big Move in Atara (ATRA) Stock?
Investors need to pay close attention to Atara (ATRA) stock based on the movements in the options market lately.
- Thomson Reuters StreetEvents
Edited Transcript of ATRA earnings conference call or presentation 8-Aug-19 12:00pm GMT
Q2 2019 Atara Biotherapeutics Inc Earnings Call
Motley FoolAtara Biotherapeutics, Inc. (ATRA) Q2 2019 Earnings Call Transcript
ATRA earnings call for the period ending June 30, 2019.
- GlobeNewswire
Atara Biotherapeutics Announces Second Quarter 2019 Financial Results and Recent Operational Progress
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- GuruFocus.com
Analysts Recommend These 2 Falling Knives
SRC Energy, Atara Biotherapeutics are expected to rebound Continue reading...
- GlobeNewswire
Atara Biotherapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 8, 2019
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- GlobeNewswire
Atara Biotherapeutics Announces Pricing of $150.0 Million Public Offering
Atara Biotherapeutics, Inc. (ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the pricing of an underwritten public offering of 6,871,727 shares of its common stock at a price to the public of $15.28 per share. In addition, and in lieu of common stock, Atara Biotherapeutics is offering to certain investors pre-funded warrants to purchase 2,945,026 shares of its common stock at a purchase price of $15.2799 per pre-funded warrant, which represents the per share public offering price for the common stock, minus the $0.0001 per share exercise price of each such pre-funded warrant. The aggregate gross proceeds from the offering are expected to be approximately $150.0 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Atara Biotherapeutics.
- GlobeNewswire
Atara Biotherapeutics Announces Proposed Offering of Common Stock
Atara Biotherapeutics, Inc. (ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that it has commenced an underwritten public offering of $125,000,000 of shares of its common stock. In connection with the proposed offering, Atara Biotherapeutics expects to grant the underwriters a 30-day option to purchase up to an additional $18,750,000 of shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the shares in the proposed offering will be sold by Atara Biotherapeutics.
- GlobeNewswire
Atara Biotherapeutics Announces Plan to Initiate Tab-cel® FDA Biologics License Application Submission Next Year
SOUTH SAN FRANCISCO, Calif., July 16, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- GuruFocus.com
5 Immunotherapy Stocks to Keep a Close Eye On
Immunotherapy is changing the face of cancer treatment as we know it, creating compelling investment opportunities
- Motley Fool
Why Atara Biotherapeutics Has Slumped in 2019
Atara's shares have collapsed this year. Here's why.
- Zacks
Atara Reports Initial Data for Multiple Sclerosis Candidate
Atara (ATRA) announces initial ATA188 phase I safety results for patients with progressive MS.
- GlobeNewswire
Atara Biotherapeutics Presents Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology (EAN)
SOUTH SAN FRANCISCO, Calif., June 29, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- GlobeNewswire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., June 25, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- Insider Monkey
Were Hedge Funds Right About Flocking Into Atara Biotherapeutics Inc (ATRA) ?
Hedge fund managers like David Einhorn, Bill Ackman, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive, but we can still get some insights by analyzing […]
- GlobeNewswire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
SOUTH SAN FRANCISCO, Calif., June 05, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- GlobeNewswire
Atara Biotherapeutics Announces Collaborator Presentation Updating Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma
Memorial Sloan Kettering Cancer Center collaborators presented results demonstrating that a regionally delivered mesothelin-targeted, autologous CAR T was well tolerated and.
- American City Business Journals
Health Care Digest: Why California biotech thrives, small company looks to crash NASH bash, meeting up at BIO
Our latest Health Care Digest is taking names and targeting the latest in biotech and health care news.
- GlobeNewswire
Atara Biotherapeutics Presents Tab-cel® Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at American Society of Clinical Oncology (ASCO) Annual Meeting
SOUTH SAN FRANCISCO, Calif., June 01, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
